ClinicalTrials.gg
CompletedNCT06213831Updated Aug 13, 2025

A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream

A Phase 1 interventional study of Ruxolitinib Cream 1.5% in Prurigo Nodularis, sponsored by Incyte Corporation. Completed at 20 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-08-13.

Sponsored by Incyte Corporation · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2025, 1 year 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
23
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Prurigo with a site in United States — 4 open to participants now, 8 under way, 4 of them phase 3. Prurigo · United States.

Enrollment
16th of 21
23 · median 140
Started
2024
with 6 others
Phase 1
2 of 23
none open now
Registered
14th of 23
by date
Lead sponsor
6 of 23
Incyte Corporation

Among the 23 studies in Prurigo with a site in United States, this one is the 16th largest by enrollment of the 21 interventional ones that give a count, is one of 7 that started in 2024, is one of 2 in phase 1, and was the 14th registered.

Prurigo

38 studies on the registry are indexed under Prurigo; 10 are open to participants now.

Browse Prurigo studies →

Open to participants now

4 of the 23 studies in Prurigo with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Prurigo studies recruiting now, 4 set no upper age limit and 2 stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Prurigo with a site in United States, or all of them as a file.
02

Study summary

This study is being conducted to determine the safety and tolerability of ruxolitinib 1.5% cream under maximal use conditions in participants with Prurigo Nodularis (PN).

03

Conditions studied

  • Prurigo Nodularis

Browse trials for

Keywords

  • Prurigo Nodularis
  • PN
  • ruxolitinib
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of PN ≥ 3 months before screening.
  • Pruriginous lesions (defined as papules, nodules, plaques, umbilicated lesions, and linear lesions) on ≥ 2 different body areas (such as right and left leg) at screening and baseline.
  • Total estimated treatment BSA ≥ 25% (excluding the scalp) at screening and baseline.
  • IGA-CPG-S score of ≥ 2 at screening and baseline.
  • Baseline PN-related WI-NRS score ≥ 7. Baseline WI-NRS score is defined as the 7-day average of WI-NRS scores before Day 1 (data from a minimum of 4 out of 7 days prior to Day 1 is needed).

Exclusion criteria

Exclusion Criteria:

  • Chronic or acute pruritus due to a condition other than PN.
  • Active AD lesions (signs and symptoms other than dry skin) within 6 months of screening and baseline.
  • Acute or chronic active or infection.
  • Any underlying condition known to be associated with the clinical presentation of PN that is not under control (stable) prior to the baseline visit.
  • Any serious illness or medical, physical, or psychiatric condition(s) that, in the investigator's opinion, would interfere with full participation in the study, including administration of study cream and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.

Other protocol-defined Inclusion/Exclusion Criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Maximal Use Ruxolitinib 1.5%

    Participants will apply ruxolitinib 1.5% cream BID through Week 4 to all pruriginous lesions. At Week 4, participants who have completed 4 weeks of treatment with no safety concerns may enter the optional 4-week treatment extension period, during which all participants will apply ruxolitinib 1.5% cream BID to existing pruriginous lesions.

    Drug: Ruxolitinib Cream 1.5%

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with Treatment-emergent Adverse Events (TEAEs)

    Defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug.

    Time frame: Up to 16 weeks, including 30 days of safety follow-up

  2. Number of participants with TEAEs leading to dose interruption or discontinuation

    Number of participants with TEAEs leading to dose interruption or discontinuation.

    Time frame: Up to 16 weeks, including 30 days of safety follow-up

Secondary outcomes

  1. Ruxolitinib pharmacokinetic (PK) parameters in plasma

    Ruxolitinib concentration in plasma.

    Time frame: Up to 16 weeks, including 30 days of safety follow-up

07

Study locations

20 sites
  • Saguaro Dermatology
    Phoenix, Arizona 85008, United States
  • Affiliated Dermatology
    Scottsdale, Arizona 85255, United States
  • First Oc Dermatology
    Fountain Valley, California 92708, United States
  • Amicis Research Center Valencia
    Northridge, California 91324, United States
  • Clinical Science Institute Clinical Research Specialists Inc
    Santa Monica, California 90404, United States
  • Advanced Pharma Cr, Llc
    Miami, Florida 33147, United States
  • Sullivan Dermatology North Miami Beach Office
    North Miami Beach, Florida 33162, United States
  • Olympian Clinical Research
    Tampa, Florida 33615, United States
  • St Lukes Clinic Dermatology Ketchum
    Ketchum, Idaho 83340, United States
  • Dawes Fretzin Clinical Research Group Llc
    Indianapolis, Indiana 46250, United States
  • Equity Medical
    Bowling Green, Kentucky 42104, United States
  • Oakland Hills Dermatology Pc
    Auburn Hills, Michigan 48326, United States
  • Revival Research Institute, Llc Troy
    Troy, Michigan 48084, United States
  • Equity Medical, Llc
    New York, New York 10023, United States
  • Red River Research Partners
    Fargo, North Dakota 58103, United States
  • Central Sooner Research
    Oklahoma City, Oklahoma 73170, United States
  • Paddington Testing Co Inc
    Philadelphia, Pennsylvania 19103, United States
  • International Clinical Research Tennessee Llc
    Murfreesboro, Tennessee 37130, United States
  • Dermresearch, Inc.
    Austin, Texas 78759, United States
  • North Texas Center For Clinical Research Ntccr
    Frisco, Texas 75034, United States
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2024 to primary completion in Jul 2025, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2024
First posted
Jan 19, 2024
StartActual
Feb 27, 2024
Primary completionActual
Jul 17, 2025
CompletionActual
Jul 17, 2025
Last update
Aug 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06213831
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Jan 19, 2024
Start date
Feb 27, 2024
Primary completion
Jul 17, 2025
Completion
Jul 17, 2025
Last update
Aug 13, 2025

Study contacts

Incyte Medical Monitor
study director · Incyte Corporation

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion